23 July 2015 – final results
In the year to 30 April, the company has recorded a loss on continuing operations of £3.9m (2014: £2.2m) although this is largely as expected given the fact that the group is still in the development stage. At the year end the group had cash of £8.4m (2014: £3.9m) helped by a successful fundraising of £8.2m net of expenses. During the year the group has made extensive progress with its Parsortix blood cell separation system and the commercial strategy is on track with first sales for research use expected in the current financial year. Although there is still some way to go before profitability we rate the shares a LONG TERM BUY.